Developmental outcomes with perinatal exposure (DOPE) to prescription opioids.
Developmental outcomes with perinatal exposure (DOPE) to prescription opioids.
复制标题
DOI：
10.1515/nipt-2023-0017
复制
发表时间：
2023-12
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
研究人员在过去20年中发现了大量证据，表明围产期阿片类药物暴露会导致后代发育障碍的风险增加，并持续到成年。使用阿片类药物治疗与妊娠、分娩和产后并发症有关的疼痛的情况一直在增加。因此，社区报告新生儿阿片类戒断综合征（NOWS）增加了300- 400%。NOWS代表了几种行为、表型和突触缺陷的初始阶段。这篇综述文章总结了处方阿片类药物的围产期暴露（DOPE）的发育结局。此外，我们还试图将这些发现与描述生命多个阶段DOPE的临床研究联系起来。由于具体的机制，DOPE的基础仍然不清楚，这篇文章的目的是提供一个框架，概念化在所有年龄段，并强调他们可能对长寿的影响。
Researchers have found considerable evidence in the past 20 years that perinatal opioid exposure leads to an increased risk of developmental disorders in offspring that persist into adulthood. The use of opioids to treat pain concerning pregnancy, delivery, and postpartum complications has been rising. As a result, communities have reported a 300–400 % increase in Neonatal Opioid Withdrawal Syndrome (NOWS). NOWS represents the initial stage of several behavioral, phenotypic, and synaptic deficits. This review article summarizes the Developmental Outcomes of Perinatal Exposure (DOPE) to prescription opioids. Moreover, we also seek to connect these findings to clinical research that describes DOPE at multiple stages of life. Since specific mechanisms that underlie DOPE remain unclear, this article aims to provide a framework for conceptualizing across all ages and highlight the implications they may have for longevity.